<DOC>
	<DOCNO>NCT02659475</DOCNO>
	<brief_summary>The goal project evaluate effectiveness tolerability novel weight management medication PHEN/TPM ER ( Qsymia® ) along nutritional lifestyle modification counsel treatment binge eat disorder ( BED ) overweight obese individual .</brief_summary>
	<brief_title>Phentermine/Topiramate Extended Release Binge Eating Disorder ( BED )</brief_title>
	<detailed_description>This exploratory open-label trial PHEN/TPM ER ( Qsymia® ) BED . It hypothesize PHEN/TPM ER ( Qsymia® ) effective , safe , well tolerate treatment BED propose conduct 1-site , 12-week , open-label , flexible dose study PHEN/TPM ER ( Qsymia® ) 10 outpatient , age 18 65 year , BED . It also hypothesize PHEN/TPM ER ( Qsymia® ) reduce weight binge eat behavior , well tolerate . The primary objective show PHEN/TPM ER ( Qsymia® ) along nutritional lifestyle modification counsel effective reduce weight overweight obese patient BED . Secondary objective show PHEN/TPM ER ( Qsymia® ) effective reduce frequency binge eat episode associate eat psychopathology safe well tolerated patient BED .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>1 . Men woman , age 18 65 year , inclusive . 2 . Subjects meet DSM5 criterion diagnosis BED . These : A. Recurrent episodes binge eat . An episode binge eat characterize following : Eating , discrete period time ( e.g. , within 2 hour period ) amount food definitely large people would eat similar period time similar condition , Sense lack control eating ( e.g. , feel one stop eat control much one eating ) B . The binge eat episode associate least three follow : eat much rapidly normal eat uncomfortably full eat large amount food feeling physically hungry eat alone embarrass much one eat feeling disgust oneself , depress , feel guilty overeat C. Marked distress regard binge eat present D. The binge eating occur , average , least week 3 month E. The binge eat associate recurrent use inappropriate compensatory behavior bulimia nervosa occur exclusively course bulimia nervosa anorexia nervosa 3 . Subjects obese ( defined BMI ≥ 30 mg/kg2 ) overweight ( define BMI ≥ 27 kg/m2 great ) presence least one weightrelated comorbidity , hypertension , type 2 diabetes mellitus , dyslipidemia . 4 . Subjects treatment weightrelated comorbidity ( hypertension , type 2 diabetes mellitus , and/or dyslipidemia ) , must stable medication regimen , define current dose medication least 3 month prior study enrollment . 1 . Current bulimia nervosa anorexia nervosa . 2 . Women pregnant , lactating , childbearing potential use adequate contraceptive measure . The following consider adequate method birth control : 1 . Intrauterine device ( IUD ) ; 2 . Barrier protection ; 3 . A contraceptive implantation system ( Norplant ) ; 4 . Oral contraceptive pill ; 5 . A surgically sterile partner ; 6 . Abstinence . Women &gt; 2years postmenopausal surgicallysterile consider childbearing potential . All female subject negative pregnancy test prior randomization . 3 . Subjects display clinically significant suicidality operationalized score ≥ 2 item 9 Beck Depression Inventory ( BDI ) ( 21 ) , suicidal ideation ColumbiaSuicide Severity Scale ( CSSRS ) ( 22 ) , homicidality . 4 . Subjects receive psychological ( e.g. , supportive psychotherapy , cognitive behavior therapy , interpersonal therapy ) weight loss ( e.g. , Weight Watchers ) intervention BED weight management begin within 3 month study entry . Subjects receive psychotherapy initiate prior 3 month begin study allow continue receive psychotherapy trial agree make change frequency nature psychotherapy course drug trial . 5 . A DSM5 diagnosis substancerelated addictive disorder ( except tobaccorelated disorder ) within 6 month prior enrollment . 6 . A lifetime DSM5 history psychosis , mania hypomania , dementia . 7 . History psychiatric disorder might interfere diagnostic assessment , treatment , compliance . 8 . Clinically unstable medical disease , include cardiovascular , hepatic , renal , gastrointestinal , pulmonary , metabolic , endocrine systemic disease . Subjects biochemically euthyroid enter study . 9 . Have history structural cardiac abnormality , valvular cardiac disease , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , stroke , serious cardiovascular problem . 10 . History seizure disorder , include clinicallysignificant febrile seizure childhood . 11 . Subjects glaucoma hyperthyroidism . 12 . Have ECG significant arrhythmias conduction abnormality , opinion physician investigator preclude study participation . 13 . Have clinically relevant abnormal laboratory result . 14 . Subjects require treatment drug might interact adversely obscure action study medication . This include antiobesity drug , psychostimulants , wakepromoting agent , drug serotonergic property , antidepressant , antipsychotic . 15 . Subjects receive psychotropic medication ( hypnotic ) within four week prior randomization , include monoamine oxidase inhibitor , tricyclic , selective serotonin reuptake inhibitor , antipsychotic , mood stabilizer , psychostimulants . 16 . Subjects receive investigational medication depot neuroleptic within three month prior randomization . 17 . Subjects know allergy PHEN/TPM ER ( Qsymia® ) constituent . 18 . Subjects urine drug screen positive drug , opinion investigator , abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>